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Biologic therapiesEpratuzumab is a B-cell-directed non-depletingmonoclonal antibody that targets CD22. It is currently being eval-
uated in two phase 3 clinical trials in patients with systemic lupus erythematosus (SLE), a disease associatedwith
abnormalities in B-cell function and activation. Themechanismof action of epratuzumab involves perturbation of
the B-cell receptor (BCR) signalling complex and intensiﬁcation of the normal inhibitory role of CD22 on the BCR,
leading to reduced signalling and diminished activation of B cells. Such effectsmay result fromdown-modulation
of CD22 upon binding by epratuzumab, as well as decreased expression of other proteins involved in amplifying
BCR signalling capability, notably CD19. The net result is blunting the capacity of antigen engagement to induce
B-cell activation. The functional consequences of epratuzumab binding to CD22 include diminished B-cell prolif-
eration, effects on adhesion molecule expression, and B-cell migration, as well as reduced production of pro-
inﬂammatory cytokines, such as IL-6 and TNF. Studies in patients treated with epratuzumab have revealed a
number of pharmacodynamic effects that are linked to themechanism of action (i.e., a loss of the targetmolecule
CD22 from the B-cell surface followed by a modest reduction in peripheral B-cell numbers after prolonged ther-
apy). Together, these data indicate that epratuzumab therapy affords a unique means to modulate BCR complex
expression and signalling.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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SLE is an autoimmune disease associated with dysregulation of both
innate and adaptive immune functions, including polyclonal B-cellthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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immune complex formation, ultimately leading to end-organ damage
and dysfunction [1–3]. There is a clearmedical need for new treatments
of SLE and, indeed, amonoclonal antibody targeting a B-cell survival fac-
tor (belimumab) was approved recently for SLE following successful
phase 3 clinical trials [4,5]. However, the anti-CD20 B-cell-depleting
monoclonal antibodies, rituximab and ocrelizumab, and agents
targeting the BAFF/APRIL axis, tabalumab and atacicept, did not meet
clinical end-points in randomized clinical trials [6–11], suggesting that
unique characteristics of a B-cell targeting agent might be required for
successful treatment of patients with SLE. Epratuzumab is a humanised
monoclonal antibody that targets CD22 on B cells and was initially de-
veloped for, and shown to be effective in, patients with B-cell malignan-
cies [12–14], where it was ﬁrst recognized that normal B cells in such
patients did not show more than a 50% reduction in peripheral blood.
It is also currently being evaluated in two phase 3 clinical trials in pa-
tients with SLE (NCT01261793 & NCT01262365). In the earlier phase
2b study, and its open label extension, epratuzumab produced sustained
improvements in disease activity in patients with active SLE [15–17].
Thus, understanding the impact of epratuzumab on B-cell function
should provide insights into the speciﬁc actions of B cells involved in
SLE pathogenesis and rational approaches to target and modulate
them effectively.2. B cells and B-cell receptor (BCR) activation play an important role
in SLE
The potential to secrete antibodies is often considered to be the
major function of B cells, but these cells performmany other functions:
they can serve as antigen-presenting cells, produce cytokines,
chemokines and other mediators, regulate the activity and function of
neighbouring cells (notably T cells and dendritic cells), and may serve
suppressive (tolerance) functions [18–22]. The most unique feature of
B cells is the expression by each B cell of a unique receptor (the B-cell
receptor (BCR)) derived from recombination of distinct genetic compo-
nents. The BCR not only conveys a speciﬁc antigen-binding capability to
each B cell, but also plays a critical role in B-cell development, activation
and survival, thus regulating the ultimate fate of B cells [23,24].
In the context of SLE, there is considerable evidence for a disturbed
homeostasis of peripheral B cells [25–27]. For example, there is a large
increase of antigen-experienced CD27+/IgD− post-switched memory
B cells [28], possibly indicative of a loss of peripheral tolerance. Addi-
tionally, expanded numbers of CD27−/IgD− (“double negative”) mem-
ory B cells have been demonstrated in active disease [29], and further
reﬁnement of this population identiﬁed CD95 (Fas) as amarker of a sub-
set of CD27− memory B cells with an activated phenotype [30]. This
subset of recent germinal centre emigres is elevated in SLE patients
with disease ﬂares, and their presence correlates with disease activity
and serologic abnormalities. Moreover, a CD19hi population [31,32], as
well as CD21lo B cell subset [33,34], were found to be characteristic of
SLE and to correlate with long-term adverse outcomes. It has also
been reported that a particular CD27− B cell subset with increased in-
tracellular Syk (Sykhi) expression also is elevated in SLE [35]. Further-
more, active SLE is characterised by expanded populations of CD27hi
plasma cells and plasmablasts, including HLA-DRhi/CD27hi cells [36]
that represent newly formed and recently divided plasma cells. The
presence of these Ig-secreting plasma cells correlateswith lupus activity
and anti-dsDNA antibody titers. Interestingly, a recent study identiﬁed a
distinct subset of activated naïve (acN) B cells as a source of antibody-
secreting cells and autoantibody production during SLE ﬂares [37]. Fi-
nally, B cells with a regulatory phenotype (so-called ‘Bregs’) appear to
be defective in SLE.Whereas CD24hi/CD38hi Bregs from healthy individ-
uals can inhibit the differentiation of Th1 cells and release IL-10, the
same population isolated form SLE patients lacked this capacity [38].
Overall, it appears that B cells are involved in a positive feed-forwardloop that maintains autoimmune memory and immunopathology in
SLE [39], and may lack appropriate regulatory elements.
In addition to phenotypic abnormalities, there is also evidence for
hyper-reactivity of B cells in SLE [40,41]. For instance, B cells from SLE
patients display augmented signalling responses, including increased
tyrosine phosphorylation and calcium ﬂux both spontaneously [42]
and in response to BCR ligation [43–45], compared to healthy control
B cells. In fact, recent data demonstrated that the hyper-responsive phe-
notype of SLE B cells (enhanced Syk phosphorylation) can be induced in
healthy B cells after incubation with SLE plasma [46]. A broad kinome
array analysis revealed changes in the activation of a number of key
kinases in SLE B cells, such as increased phosphorylation of
phosphoinositide 3-kinase and Akt-1 (PKB), as well as abnormal phos-
phatase activity, indicated by decreased SHIP phosphorylation [47].
SLE B cells also show constitutively enhanced expression of co-
stimulatory molecules, such as CD40L, defective signalling through
FcɣRIIb, enhanced cytokine production, spontaneous Ig class-switching
and production, and possess markedly enhanced mutational activity in
their Ig gene repertoire [41,48–51]. However, B cells from patients
with severe disease have been shown to be hypo-responsive in relation
to cytokine production after toll-like receptor (TLR) stimulation [52], al-
though they are hyper-proliferative in response to combined stimula-
tion through BCR/CD40 or BCR/TLR pathways [53]. Interestingly, in
spite of an overall reduced level of Lyn, the lipid rafts of B cells from
SLEpatients are large and intensely stained, and contain increased levels
of phosphorylated Lyn, suggestive of an enhanced activation state [54]
or possibly enhanced 'tonic' (ligand-independent) signalling. Finally,
both SHP-1 and CD45 are down-regulated in some patient B cells [55],
possibly indicating that compensatory pathways are operative in dis-
ease. By contrast, there is low activity of PTEN, a phosphatase that serves
to down-regulate BCR downstream signals, in SLE B cells [45]. Overall,
the data strongly suggest that BCR-related pathways are aberrantly
up-regulated in SLE B cells. This is in line with the results of genome-
wide association studies which linked B cell signalling genes, such as
PTPN22, BANK1 and BLK, with SLE [56–58]; very recent data also identi-
ﬁed an SLE risk allele in the PXK genewhich encodes a protein shown to
be involved in BCR internalisation [59].
3. The principal role of CD22 is to regulate the BCR
CD22 is a membrane receptor found on B cells and is a member of
the Siglec family of proteins (designated Siglec-2). The Siglec family
members aremainly expressed on immune cells, are homologous in se-
quence and also share structural features, most notably the presence of
Ig-like extracellular domains and the capacity to recognize sialic acid-
containing ligands [60,61]. CD22 primarily exists as a protein containing
7 Ig-like domains, themostmembrane-distal of which (domain 1) is re-
sponsible for ligand binding. The expression of CD22 is generally
regarded as being restricted to B cells. CD22 is initially expressed on im-
mature B cells, is present throughout most of B-cell development, being
most highly expressed on naïve B cells [62], but is lost on plasmablasts
and plasma cells. Nevertheless, memory B cells and germinal centre B
cells from human tonsils express CD22 to a signiﬁcant degree [63].
Binding of antigen to the BCR complex triggers a cascade of phos-
phorylation events and changes in calcium (Ca2+) ﬂux that ultimately
drive B-cell activation (reviewed in [64]). Upon BCR cross-linking, Lyn
phosphorylates the immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) on CD79α/βwhich creates docking sites for other protein tyro-
sine kinases, such as spleen tyrosine kinase (Syk), which in turn phos-
phorylate and recruit the adaptor molecule, BLNK/SLP65 (B-cell linker
protein). BLNK/SLP65 forms a scaffold for the association of numerous
signalling components, including Vav-1, Btk (Bruton's tyrosine kinase),
and phospholipase Cɣ2 (PLCɣ2). Activation of the inositol tri-
phosphate/diacylglycerol pathway by PLCɣ2 promotes Ca2+ release
from intracellular stores, which in turn triggers an inﬂux of calcium
through the opening of Ca2+ release-activated channels (CRACs), and
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also be regulated via plasma membrane Ca2+ ATPase (PMCA4).
Based on a wealth of published data, CD22 is believed to play a pri-
mary role as an inhibitory co-receptor of the BCR. In this manner, BCR-
activation initiates phosphorylation of key tyrosine residues on the in-
tracellular region of CD22 by Lyn and other Src family members. Once
phosphorylated, such tyrosine residues become docking sites for Src ho-
mology (SH2) domain-containing proteins, such as SHP-1, ultimately
leading to de-phosphorylation of BCR signalling components and a re-
duction in Ca2+ ﬂux in B cells [65,66]. By this mechanism, CD22 serves
to control the threshold of the BCR response. Although BCR-related re-
search has focused on antigen-driven events and their importance to
immune function, ligand-independent (or ‘tonic’) signalling also has
been described and appears to play a key role in normal B-cell develop-
ment, maturation and survival [67–69]. However, the role that CD22
plays in modulating ‘tonic’ BCR signals has not been investigated.
It iswell accepted that combinatorial signalling through BCR andTLR
pathways shapes the outcome of B-cell activation [70] and, in general,
simultaneous BCR cross-linking synergistically enhances TLR responses
and vice versa [71–73]. Other work has indicated that there is cross-talk
between BCR and CD40/CD40L pathways [74,75], and CD40L activation
can inﬂuence the phosphorylation of CD22 [76]. Moreover, data from
CD22-deﬁcient mice argue that CD22 negatively regulates TLR signals
in a constitutive manner [77,78] and CD40 stimulation is able to rescue
B-cell apoptosis and induce enhanced proliferation of B cells fromCD22-
deﬁcient mice [79,80], suggesting that the regulatory function of CD22
may be exerted beyond the BCR pathway per se.
In resting B cells, CD22 and BCR proteins are distributed
homogenously on the B-cell surface and probably in physically separate
microdomains of the cell membrane. Upon ligation, the BCR migrates
into distinct areas in the membrane where it is eventually internalised.
This process is important for the B cell to take up BCR-bound antigen for
processing and eventual presentation to T cells. After binding cognate
antigen, the BCR migrates to clathrin-coated pits and lipid rafts, where
clathrin is also located [81,82]. In resting B cells, CD22 is also normally
excluded from lipid rafts, but may reside in other clathrin-rich regions
of the plasma membrane [83]. Following BCR ligation, however, CD22
migrates into the same vicinity as the BCR, although there is a debate
as to whether this occurs within lipid rafts or other domains [76,
84–86]. It appears that the BCR may be constitutively in association in
some B-cell lines and tonsil B cells [87,88].
The ligand for CD22,α2,6-sialic acid, decorates a large number of cell
surface and soluble proteins, including CD45, IgM and CD22 itself. Li-
gands can be presented to CD22 in cis (on the same cell) or in trans
(on opposing cells or on soluble proteins). Interactions in trans have
been postulated to regulate B-cell adhesion events and may also be im-
portant for recognition of ‘self’ [22,89]. However, in terms of CD22 reg-
ulation of the BCR, the consensus view is that cis ligand interactions play
a predominant role, although two seemingly conﬂicting models have
been proposed [90]. In the ﬁrst, cis interactions increase CD22-BCR asso-
ciation because several BCR-related proteins express high levels of CD22
ligand, whereas in the second model, cis interactions with non-BCR-
related proteins, such as CD22 itself, result in reduced association with
the BCR. Both models may be correct in different contexts. It is impor-
tant to note that epratuzumab does not bind to the ligand-binding do-
main 1 of CD22 and does not interfere with ligand binding and
therefore would not interfere directly with either mechanism. CD22
can also interact with neighbouring cell surface proteins in cis through
covalent protein–protein interactions, independent of the presence of
the α2,6-sialic acid ligand [91].
In a broader context, CD22 is considered to be one of several B-cell
surface receptors that have been called “response regulators” and
which are responsible for ﬁne-tuning BCR signals [92,93]. Other “re-
sponse regulators” include CD19, CD72 and FcɣRIIb. The “CD19/CD22
signalling loop”, providing positive versus negative regulatory activity
on BCR signalling, respectively [94], represents a major pathway forBCR ﬁne-tuning, whereby the two molecules modulate the signalling
competence of each other as well as of the BCR itself.
4. Epratuzumab can down-modulate BCR-driven signalling
Given the normal role that CD22 plays in regulating BCR-driven sig-
nalling, it was important to explore the impact of epratuzumab on the
downstream events following BCR engagement. The regulatory activity
of CD22 is initiated by CD22 phosphorylation, and immunoprecipitation
data in B-cell lines demonstrated that epratuzumab can rapidly induce
the direct phosphorylation of CD22 [95] as well as its migration to
lipid rafts [86]. Moreover, more recent studies have shown enhanced
CD22 phosphorylation in primary human B cells with epratuzumab
followed by direct co-localisation of CD22 with SHP-1 (Fleischer,
Lumb & Dörner, unpublished results).
Sieger et al. [96] usedﬂow cytometry to show that epratuzumabpre-
incubation with primary B cells in vitro diminished the subsequent
phosphorylation of both Syk and PLCɣ2, and reduced Ca2+ ﬂux after
BCR stimulation. Inhibitory effects were demonstrated in both CD27−
naïve B cells and in CD27+ memory B cells, and occurred whether
epratuzumab was used as an intact IgG or as a F(ab′)2 fragment lacking
Fc, indicating no role for Fc receptor binding. In other experiments, a di-
rect effect of epratuzumab on the Ca2+ efﬂux pump, PMCA4, was sug-
gested. Data supporting the potential for epratuzumab to dampen
Ca2+ ﬂux were also obtained in experiments using B cells from
human CD22 transgenic mice [97], in which the mouse B cells express
human CD22.
In a study of peripheral bloodmononuclear cells from60healthy do-
nors [98], epratuzumab inhibited anti-BCR-induced proximal phos-
phorylation events, including decreasing phospho-Syk, -PLCɣ2, -Btk
and -Slp76, in naïve B cells, as well as class-switched and pre-
switched memory B-cell subsets. Interestingly, somewhat more distal
BCR signals were modulated differentially in different B-cell subsets,
such that phosphorylation of ERK and p38, for example, were inhibited
in memory B-cell subsets but broadly upregulated in naïve B cells. In-
triguingly, the interaction of intravenous immunoglobulin (IVIg) with
CD22 on B cells has been shown to inhibit proximal BCR signals and to
activate phosphorylation of p38 and ERK, thereby promoting apoptosis
[99]. There was signiﬁcant donor to donor variation in responses across
the 60 donors, which may be relevant in relation to predicting individ-
ual patient responses.
5. Epratuzumab decreases CD22 and components of the BCR
complex from the B-cell surface
Epratuzumab, like other CD22 antibodies, is known to induce the
loss of its target antigen from the cell surface [95,97,100]. The process
occurs rapidly in vitro (within 30–45 min), reaching a maximum of
about 70–80%. The principal mechanism is internalisation into the B
cell. Epratuzumab directly induces the rapid movement of CD22 into
(or into the vicinity of) lipid raft domains in the absence of BCR activa-
tion [86], and likewise induces the co-localisation of CD22with the BCR
component, CD79α [96], which is then internalised along with CD22.
This suggests that epratuzumab induces the removal of components of
the BCR complex through an “innocent bystander” mechanism. Both
the co-localisation of CD22with the BCR and subsequent internalisation
events can be induced with a F(ab′)2 fragment of epratuzumab, but not
with a monovalent Fab, arguing that such pathways require bivalency
but not the Fc domain of the antibody. Although there are no data
with epratuzumab itself, studies with other anti-CD22 antibodies have
shown that internalised proteins can potentially be delivered both
into lysosomal compartments for degradation [101] or recycled from
endosomal compartments [83,102,103], although recycling occurs at a
much slower rate compared to other recycling receptors.
In addition to CD22, epratuzumab also induced the loss of a range of
other proteins from the B-cell surface in vitro, including CD19, CD79β
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and CD18, was largely unchanged [100]. An alternative mechanism
was suggested for this surface clearance, namely trogocytosis (from
the Greek “to gnaw”), or the transfer of material from one cell to a
neighbouring cell. Importantly, the loss of CD19 and CD22 from the B-
cell surface was associated with a concomitant up-regulation of these
proteins on phagocytic cells, notably monocytes. Unlike internalisation,
which is an Fc-independent process, trogocytosis is dependent on inter-
actions with Fc receptors and does not take place if an F(ab′)2 fragment
of epratuzumab is employed. The relative contribution of internalisation
and trogocytosis to the clearance of components of the BCR complex
from the surface of individual B-cell subsets is currently unknown.
Overall, one can view internalisation and trogocytosis as
representing different but complementary mechanisms that decrease
expression of components of the BCR complex from the B-cell surface.
Reduction of CD19may be of particular relevance for SLE, because poly-
morphisms of CD19 have been associated with susceptibility to disease,
and loss of CD19 has been shown to attenuate activation of B cells by
raising the BCR signalling threshold [104,105].
6. Physical interactions between CD22 and the BCR complex are
known to inhibit B-cell activation
Inducing direct interaction of CD22with the BCR dampens B-cell ac-
tivation. For instance, co-expression of α2,6-sialic acid CD22 ligands
with antigen on target cells leads to diminished activation of B cells
[89]. The use of synthetic antigenic polymers displaying both a T-
independent antigen (dinitrophenol) and CD22 ligands that physically
bring CD22 and the BCR together leads to dampened BCR signalling
in vitro and reduced antibody responses in vivo [106,107], whilst
antibody-induced clustering of CD22 with the BCR also leads to damp-
ened Ca2+ ﬂux [108]. By contrast, sequestration of CD22 away from
the BCR using antibody-coated beads lowers the activation threshold
and increases proliferation of human B cells [65]. Finally, liposomes pre-
senting both antigen and CD22 ligandsmarkedly inhibited B-cell activa-
tion events, enhanced apoptosis in vitro, and diminished antibody
responses in vivo [22] and lymphocytes bearing foreign antigen as a
model of donor-speciﬁc transfusion (IgMHEL cells) deleted antigen-
reactive B cells in vivo through BIM-dependent apoptosis [109]. This
phenomenon has been termed STALing (SIGLEC-engaging tolerance in-
ducing antigenic liposomes) [110], and was shown to be successful in
preventing antibody responses in a preclinical model of haemophilia A
[22].
The endocytosis of the BCR is a normal event that is important for its
functional activity. Recent work [111] has shown that antigens that can
induce co-clustering of the BCR and CD22 promote rapid BCR endocyto-
sis even at low concentrations, whereas slower endocytosis occurs with
antigens that bind only the BCR. This is likely to be relevant to the situ-
ation with epratuzumab, given its propensity to induce clustering of
CD22 with the BCR in lipid raft domains with a high internalisation
rate. Moreover, since CD22 appears to exist primarily as large homo-
multimeric complexes on the cell surface [112], formed because of in-
teractionsmediated by cis ligand interactions or via covalent homotypic
binding (neither of which would be disturbed by epratuzumab), an in-
triguing hypothesis is that epratuzumab pulls these very large com-
plexes into association with the BCR, maximizing the clearing of the
BCR from the B-cell surface.
7. Epratuzumab exerts functional effects on B-cell activation
Physiological activation of B cells takes place in a complex microen-
vironment, in which B cells are likely receiving a combination of signals,
depending on their location, the presence of other cells and cytokines,
the nature of a given immune challenge and disease state. More recent
studies investigating the mechanism of action of epratuzumab have
attempted to mimic aspects of this complexity by, for example,providing combinatorial signals, assessing B cells co-cultured with
other leukocytes, and comparing SLE with healthy donor B-cell
responses.
B cells from the blood of patientswith SLE display enhanced prolifer-
ative responses to anti-BCR activation and also to combinations of anti-
BCR plus CD40L or anti-BCR plus CpG oligodeoxynucleotides (used as a
TLR9 agonist) [53]. Epratuzumab in these culture systemswas shown to
inhibit the enhanced proliferative responses of SLE B cells, but not those
from healthy donors. By contrast, other data have demonstrated that,
under certain conditions, an enhancement of BCR-driven proliferation
of tonsillar B cells or B-cell lines can be observed with some CD22 anti-
bodies, although such responses typically require the antibodies to be
cross-linked in solution or to be immobilised on a surface [65,113,
114]. Importantly, enhanced proliferation was a feature of CD22 anti-
bodies that could block ligandbinding,whereas non-ligand blocking an-
tibodies lacked activity [115]. Particular care is neededwhen comparing
data with transformed B cell lines and primary B cells, given the para-
doxical consequences of BCR activationwhich can enhance proliferation
of primary mature B cells [65], but induce apoptosis of transformed B
cell lines [116]. With this in mind, a recent study using epratuzumab
showed that immobilisation of the antibody (coating on plates or cap-
tured onto endothelial cells) in the absence of BCR activation was able
to induce apoptosis and decrease the viability of Ramos and Daudi
human B-lymphoma lines [117]. Notably, the inhibition of B-cell prolif-
eration that occurs following direct cell–cell interaction with dendritic
cells has been shown to be CD22-dependent [118].
The effect of epratuzumab on cytokine production by B cells also has
been investigated. Epratuzumab inhibited the secretion of the pro-
inﬂammatory cytokines TNF and IL-6 after anti-BCR or anti-BCR plus
CpG stimulation of puriﬁed blood B cells from both healthy donors
and SLE patients [119]. In contrast, the production of IL-10 by B cells
(or induction of IL-10+ cells) was not signiﬁcantly affected by
epratuzumab under any conditions, although the balance between
pro-inﬂammatory and regulatory cytokines (IL-6/TNF versus IL-10)
was altered in favour of the latter. In this regard, epratuzumab enhanced
production of IL-10 by human tonsil naïve B cells stimulated with anti-
BCR plus R848 (a TLR7 agonist on B cells) [63]. There was a donor-
dependent relationship between the absolute expression of the TLR7 re-
ceptor and the capacity for B cells to produce IL-10, whichmay contrib-
ute to the heterogeneity of the response and the capacity for
epratuzumab to affect that response.
8. Pharmacodynamic studies in SLE patients are providing insights
into the functional impact of epratuzumab on B-cell function
As onemight predict based on the in vitro data already discussed, an
initial pharmacodynamic effect observed in patients treated with
epratuzumab might be the loss of CD22 from the B-cell surface [100,
120]. The maximal effect (approximately 70–80% loss relative to pre-
dose) was noted one week after the ﬁrst dose of epratuzumab, was
maintained throughout the treatment period, and was observed on
naïve, memory/activated and transitional B-cell subsets. Furthermore,
CD22 levels remained low for more than 2 years in patients receiving
long-term treatment with epratuzumab [120]. However, the effect ap-
peared to be reversible: a return to baseline value was observed after
dosing ceased, at least at the lower doses, although it is not clearwheth-
er this represents the expression of new CD22 protein on circulating B
cells or simply the release of new B cells into the periphery that had
not internalised their CD22. It should be noted that approximately
20–30% of CD22 remains on the B-cell surface and cannot be further re-
duced by increasing doses of epratuzumab, suggesting that a subset of
CD22 molecules exists that cannot be dynamically regulated by
epratuzumab. Finally, in keeping with in vitro data, B cells from SLE pa-
tients treatedwith epratuzumab show a reduction in their expression of
CD19, which may contribute to epratuzumab's activity in SLE patients
[100].
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treated patients was a reduction of B-cell numbers in the blood, al-
though this effect is moderate and the kinetics protracted. In a small
open-label study [30], where 12 SLE patients received 4 doses of
epratuzumab, a maximum decline of approximately 30% of total B
cells was noted, and CD27− naïve B cells appeared to be more affected
that CD27+ memory B cells. Another small study in patients with
Sjögren's syndrome noted a mean reduction of around 50% after 4 infu-
sions [121]. In a subsequent larger SLE study, very small changes were
noted after a single cycle of treatment with epratuzumab, although
there was evidence for a small decrease in the proportion of CD22+
naïve B cells and a commensurate increase in the proportion of CD22+
memory B cells [120]. Data from the SLE open-label extension study
demonstrated that a median 50–60% reduction of total B cells occurred
after 9–12months and that this did not increase beyond that time point,
even in patients receiving epratuzumab for up to 3 years.
Overall, these data suggest that, unlike rituximab, epratuzumab is not
a B-cell-depleting antibody. Rituximab targets CD20onB cells and is capa-
ble of causing an almost complete removal of at least blood B cells in a
matter of days, which is often sustained for long periods of time [136], al-
though the presence of recently generated IgA+ plasmablasts indicates
that this agent does not completely inhibit B-cell precursors [122]. In
vitro studies demonstrate that epratuzumab is unable to induce
complement-dependent cytotoxicity (CDC) or direct apoptosis of B cells
in culture, and induces onlymodest antibody-dependent cellular cytotox-
icity (ADCC) [114,123], in contrast to rituximab, which can mediate all
three depletion mechanisms. This lack of effector-driven B-cell depletion
is probably a consequence of the propensity of epratuzumab to induce
internalisation or trogocytosis of CD22,making it an unsuitable target an-
tigen to act as an ‘anchor’ for effective cell ablation [124]. In a similarman-
ner, the capacity of different anti-CD20 monoclonal antibodies to induceFig. 1. The proposed unique mode of action of epratuzumab: BCR modulation leading to dimin
tracellular phosphorylation events (e.g., Syk, PLCɣ2) and changes in Ca2+ ﬂux that eventually ac
ultimately driving B-cell activation; CD19, as a positive regulator of the BCR, further ampliﬁes B-c
of BCR-relatedproteins, such as CD19and CD22 itself, from theB-cell surface throughmechanism
likely result in less responsive B cells. C: epratuzumab also induces direct co-localisation of phosp
engagement, resulting in diminished B-cell stimulation. The overall impact is inhibition of B-ce
production, ultimately reducing subsequent autoimmune and inﬂammatory events mediated bcell depletion in vitro is inversely related to their capacity to be
internalised [125].
With this in mind, it is pertinent to ask for an explanation for the B-
cell reductions observed in patients receiving epratuzumab. It has been
established that the normal maturation of B cells requires BCR signals
both in the presence of antigen or its absence ('tonic' signalling) such
that, for example, removal of the BCR or deletion of CD79α/β prevents
maturation of B cells or causes them to revert to a less differentiated
phenotype, or to be ablated [126–129]. Indeed, the expression of the
BCR appears to be necessary for the survival of all B cells [69]. Given
the potential induction of sustained, chronic inhibition of BCR signalling,
it is possible that epratuzumab curtails the normal pathway of B-cell
maturation or survival. Notably, mice with mutated non-functional
ITIM residues on CD22 have enhancedmaturation of transitional toma-
ture B cells [130] and accelerated proliferation of naïve B cells following
antigen stimulation, resulting in rapid generation of plasmablasts/plas-
ma cells and faster antibody production [131]. Another hypothesis for
reduced B cells relates to possible changes in B-cell migration and traf-
ﬁcking into different tissue compartments. For example, the VLA4/
CXCL12/CXCR4 “zip code” serves to keep immature B cells in the bone
marrow and prevents further maturation [132,133]. In this regard, it
has been shown that epratuzumab enhances expression and function
of β1 integrins (notably α4β1) on B cells and increases their migration
to CXCL12 [62]; therefore, an epratuzumab-mediated alteredmigratory
capacity could be operative in preventing release and/or maturation of
immature B cells in the bone marrow. Furthermore, the organisation
of germinal centres into dark and light zones appears to depend on op-
posing gradients of CXCL12 and CXCL13 [134], and it has been speculat-
ed that VLA4 ligandsmight be expressed at higher levels in the germinal
centres [135], raising the intriguing possibility for modulation of B cells
within the germinal centre.ished B-cell activation. A: BCR engagement with antigen normally triggers a cascade of in-
tivate downstream signals (e.g., NFκB, ERK)which then initiate changes in gene activation,
ell signalling capacity. B: In resting B cells, epratuzumab induces physical down-regulation
s such as internalisation and trogocytosis, leading to an alteredBCR complexwhichwould
horylatedCD22 (and SHP-1)with theBCR and limits the extent of BCR signalling after BCR
ll functional activation, including decreased proliferation and pro-inﬂammatory cytokine
y B cells.
1084 T. Dörner et al. / Autoimmunity Reviews 14 (2015) 1079–1086Regardless of the mechanism, whether epratuzumab inﬂuences a
particular checkpoint in the maturation of B cells has yet to be fully de-
ﬁned. However, it is clear that understanding precisely how B cells are
changed in patients in response to epratuzumab therapy is limited by
the fact that we are effectively restricted to monitoring changes in the
blood compartment, whilst the real ‘site of action’ is likely to be the lym-
phoid tissues or affected organs that are not readily available for study.
As discussed earlier in this review, there is evidence for a number of B-
cell abnormalities in the SLE blood compartment, and these actually are
amenable to investigation. For example, the CD27−/IgD− double-
negative memory B-cell population that expresses high levels of CD95
is known to be elevated in SLE patients with disease ﬂares and correlate
with disease activity and serologic abnormalities [30]. Interestingly,
there is a gradual decline in the numbers of these cells after long-term
treatment with epratuzumab [120].9. Conclusions
Activated B cells are believed to play a role in the pathogenesis of SLE
by inducing several autoimmune/inﬂammatory processes, which in-
clude the production of autoantibodies, antigen presentation, support
of T-cell differentiation, and/or production of pro-inﬂammatory cyto-
kines. The key aspects of the mechanism of action of epratuzumab are
summarised in Fig. 1, and indicate that this agent in essence enhances
the normal inhibitory function of CD22 on the BCR. Firstly, by targeting
CD22, epratuzumab induces physical down-regulation of BCR complex
components on resting cells, which would likely result in less respon-
sive B cells. Secondly, epratuzumab limits the extent of BCR signalling
after BCR engagement. The overall effect is inhibition of B-cell activa-
tion, ultimately reducing subsequent autoimmune and inﬂammatory
events mediated by B cells. It is thus intriguing to speculate how
epratuzumab may also be therapeutically active in other B-cell-
implicated autoimmune diseases.Conﬂicts of interest
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plex and intensiﬁcation of the normal inhibitory role of CD22 on the
BCR, leading to reduced signalling and diminished activation of B cells.Acknowledgements
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